Fig. 4From: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trialChange from baseline in HbA1c and body weight by gender (a, c) and age (b, d) in SUSTAIN 6. ETD estimated treatment differenceBack to article page